Inozyme Pharma, Inc. financial data

Symbol
INZY on Nasdaq
Industry
Pharmaceutical Preparations
Location
321 Summer Street, Suite 400, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Inozyme Pharma, LLC (to 1/5/2017)
Latest financial report
10-K - Q4 2024 - Mar 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 734 % -43.8%
Debt-to-equity 69.3 % +86.3%
Return On Equity -115 % -106%
Return On Assets -68.1 % -67.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 64.2M shares +3.86%
Common Stock, Shares, Outstanding 64.2M shares +4%
Entity Public Float 199M USD -0.06%
Common Stock, Value, Issued 6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 62.8M shares +21.2%
Weighted Average Number of Shares Outstanding, Diluted 62.8M shares +21.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 83.2M USD +51.8%
General and Administrative Expense 20.8M USD +0.01%
Operating Income (Loss) -104M USD -37.5%
Nonoperating Income (Expense) 2.01M USD -55.2%
Net Income (Loss) Attributable to Parent -102M USD -43.4%
Earnings Per Share, Basic -1.62 USD/shares -18.2%
Earnings Per Share, Diluted -1.62 USD/shares -18.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 21.1M USD -39.1%
Cash, Cash Equivalents, and Short-term Investments 113M USD -40%
Assets, Current 121M USD -38.5%
Property, Plant and Equipment, Net 784K USD -46.5%
Operating Lease, Right-of-Use Asset 562K USD -50.1%
Assets 123M USD -38.7%
Accounts Payable, Current 2.53M USD +117%
Employee-related Liabilities, Current 3.67M USD -4.48%
Accrued Liabilities, Current 16M USD +26.5%
Liabilities, Current 33.9M USD +131%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 65.4M USD +8.26%
Accumulated Other Comprehensive Income (Loss), Net of Tax 69K USD +68.3%
Retained Earnings (Accumulated Deficit) -388M USD -35.7%
Stockholders' Equity Attributable to Parent 57.8M USD -58.8%
Liabilities and Equity 123M USD -38.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -24.5M USD -38%
Net Cash Provided by (Used in) Financing Activities 159K USD -99.2%
Net Cash Provided by (Used in) Investing Activities 10.4M USD -24.5%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 64.2M shares +4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 125M USD +41%
Deferred Tax Assets, Gross 126M USD +40.5%
Operating Lease, Liability 913K USD +30.4%
Payments to Acquire Property, Plant, and Equipment 32K USD -81.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -102M USD -43.8%
Lessee, Operating Lease, Liability, to be Paid 944K USD
Property, Plant and Equipment, Gross 3.94M USD +1.52%
Operating Lease, Liability, Current 913K USD +0.33%
Lessee, Operating Lease, Liability, to be Paid, Year Two 944K USD -7.09%
Lessee, Operating Lease, Liability, to be Paid, Year One 944K USD -7.09%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 31K USD
Deferred Tax Assets, Operating Loss Carryforwards 52.8M USD +22.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 154K USD -62.4%
Share-based Payment Arrangement, Expense 7.95M USD +12.9%
Interest Expense 1.4M USD +80.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%